tpst-1495
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 22, 2020 (NCT04344795)
Timeline
Indications
Studied for
- Adenomatous Polyposis Coli · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
Mechanism of action
- Prostanoid EP4 receptorINHIBITOR
PTGER4 inhibitor
- Prostanoid EP2 receptorINHIBITOR
PTGER2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06557733 | Phase 2 | Feb 4, 2025 | National Cancer Institute (NCI) |
| NCT06129604 | Phase 2 | Jan 31, 2024 | University of Oklahoma |
| NCT04344795 | Phase 1 | Apr 22, 2020 | Tempest Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2025 |
| Tempest Therapeutics | For profit | 1 | 1 | 1 | 2020 |
| University of Oklahoma | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1